Join Us

ASBM Writes FDA Commissioner on Distinguishable Naming

Read More

Latin American Physician Survey Shows Support for WHO Proposal

Read More

ASBM Meets with Administration on Biosimilar Naming

Read More

ASBM's Gewanter Praises FDA for Clear Naming, Urges Greater Label Transparency

Read More

ASBM Presents at 60th WHO Naming Meeting

Read More

Prominent pharmacists write FDA on Labeling

Read More

New ASBM Survey Provides Physicians' Views on Biosimilar Labeling

Read More

ASBM Educates Pharmacists as FDA Approves First Biosimilar

Read More

FDA Approves First Biosimilar

Read More

State Legislation on Substitution

Read More

The Issue: Putting Patients First

Biologics are advanced prescription drugs to treat cancer, rheumatoid arthritis and other debilitating diseases. As early as 2014, the first attempts to copy these drugs, known as biosimilars, are expected to be approved. Since 2010, The Food and Drug Administration has been consulting patient groups, physicians and industry on how to best ensure safe access to these powerful medicines. The Alliance for Safe Biologic Medicines works ensure patient safety remains the priority, submitting formal comments to FDA in February of 2012, and its members testifying at an FDA hearing in May 2012 and before several state legislatures, and conducting educational forums nationwide. LEARN MORE

Get Involved

Sign up for updates

Latest News
Member Partners

The Alliance for Safe Biologic Medicines is an organization composed of diverse healthcare groups and individuals—from patients to physicians, biotechnology companies that develop innovative and biosimilar medicines and others who are working together to ensure patient safety is at the forefront of the biosimilars policy discussion.Read More

Newsletters